Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Ambu A/S: Ambu receives FDA clearance for disposable colonoscope in the US

Ambu A/S
Posted on: 09 Jan 18

With this milestone Ambu is cleared to address the +15 million annual procedure market for colonoscopy in the US.

Ambu already operates in the field of single-use endoscopy for pulmonary (visualisation of the airways) with aScope, a ~5m annual procedure market, and has sold more than 700,000 aScopes since the launch in 2013.

'We are very pleased with the approval by the FDA, which we see as a clear signal that there is a need for mitigating the risks of cross contamination within endoscopy, a risk that was recently ranked as the 2 nd most critical health hazard in ECRI's report for 2018. The FDA approval marks a positive upgrade of our business potential,' says Lars Marcher, CEO of Ambu.

Contact and further information
Lars Marcher, President & CEO - Phone +45 5136 2490     . E-mail:

Company announcement no. 13_2017_18

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Ambu A/S via GlobeNewswire

Last updated on: 10/01/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.